Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADA | P00813 | 9/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6133941 | 0.99 | ADA (0.98) | ADA | |
| SCHEMBL6170497 | 0.91 | ADA (0.84) | ADA | |
| SCHEMBL6940305 | 0.84 | ADA (0.72) | ADA | |
| SCHEMBL6171992 | 0.84 | ADA (0.72) | ADA | |
| SCHEMBL6172584 | 0.84 | ADA (0.72) | ADA | |
| SCHEMBL6134586 | 0.84 | ADA (0.75) | ADA | |
| SCHEMBL6174704 | 0.84 | ADA (0.75) | ADA | |
| SCHEMBL5672318 | 0.83 | ADA (0.71) | ADA | |
| SCHEMBL6172027 | 0.83 | ADA (1.00) | ADA | |
| SCHEMBL6168397 | 0.83 | ADA (1.00) | ADA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1098885-B9 | IMIDAZOLE COMPOUNDS AND THEIR USE AS ADENOSINE DEAMINASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-05-18 | — | — | EP | claimed |
| EP-1098885-B1 | IMIDAZOLE COMPOUNDS AND THEIR USE AS ADENOSINE DEAMINASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO (JP) | 2004-11-17 | — | — | EP | claimed |
| US-6359145-B1 | ADENOSINE DEAMINASE INHIBITOR; ANTIINFLAMMATORY AGENTS; IMMUNOSUPPRESSANT | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-03-19 | — | — | US | claimed |
| US-20220001015-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | SEAPORT THERAPEUTICS, INC. | 2022-01-06 | — | — | US | disclosed |
| US-6908940-B2 | Imidazole compounds and their use as adenosine deaminase inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-21 | — | — | US | disclosed |
| EP-1098885-B9 | IMIDAZOLE COMPOUNDS AND THEIR USE AS ADENOSINE DEAMINASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-05-18 | — | — | EP | disclosed |
| EP-1098885-B1 | IMIDAZOLE COMPOUNDS AND THEIR USE AS ADENOSINE DEAMINASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO (JP) | 2004-11-17 | — | — | EP | disclosed |
| US-20040097571-A1 | Imidazole compounds and their use as adenosine deaminase inhibitors | ASTELLAS PHARMA INC. (JP) | 2004-05-20 | — | — | US | disclosed |
| US-6596738-B1 | Inhibiting activity to adenosine deaminase (hereinafter described as ADA) An adenosine deaminase inhibiting agent comprising a compound of the formula (I): | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-22 | — | — | US | disclosed |
| US-6359145-B1 | ADENOSINE DEAMINASE INHIBITOR; ANTIINFLAMMATORY AGENTS; IMMUNOSUPPRESSANT | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220001015-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | LIPA, MALT1, SGMS1 | ADA 793/4885 |
| US-20040097571-A1 | Imidazole compounds and their use as adenosine deaminase inhibitors | ADA, AMPD2, AMPD1 | ADA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.